Skip to main
SGMT

SGMT Stock Forecast & Price Target

SGMT Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 67%
Buy 17%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

Sagimet Biosciences is a promising biopharmaceutical company with a focus on developing innovative treatments for a range of diseases, including metabolic dysfunction-associated steatohepatitis (MASH), acne, and certain forms of cancer. Its drug candidate, denifanstat, has shown promising results in clinical trials for the treatment of acne and is expected to enter a Phase 3 trial later this year. Additionally, the company's second FASN inhibitor, TVB-3567, has the potential to be a more potent and effective treatment for acne. Overall, the company's pipeline and strategic focus on non-antibiotic, mechanism-based therapies suggest potential success in the highly competitive acne market. With a strong cash position and a solid clinical and regulatory risk profile, Sagimet Biosciences may have the potential for significant growth in the future.

Bears say

Sagimet Biosciences is facing potential risks including the possibility of denifanstat not demonstrating expected efficacy or safety in treating acne, potential failures of TVB-3567 or topical FASN inhibitor for acne treatment, and potential setbacks in clinical, regulatory, patent, or commercial aspects of their pipeline, all of which could lead to increased competition and hinder their success in the market.

SGMT has been analyzed by 6 analysts, with a consensus rating of Buy. 67% of analysts recommend a Strong Buy, 17% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Sagimet Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Sagimet Biosciences Inc (SGMT) Forecast

Analysts have given SGMT a Buy based on their latest research and market trends.

According to 6 analysts, SGMT has a Buy consensus rating as of Aug 13, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $26.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $26.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Sagimet Biosciences Inc (SGMT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.